Recently, Sutro Biopharma announced that the US Food and Drug Administration (FDA) has granted STRO-001 the orphan drug qualification for the treatment of multiple myeloma (MM). STRO-001 is a potential first antibodyRead More…
The Success of Seattle Genetics/Wutian ADC Adcetris for Phase III Clinical Surgery of Peripheral T Cell Lymphoma (PTCL)
October 03, 2018 – Seattle Genetics and Takeda recently announced the evaluation of antibody conjugates Adcetris (brentuximab vedotin) for the treatment of peripheral T-cell lymphoma (PTCL, also known as mature Phase IIIRead More…
Seattle Genetics Launched the Phase II Clinical Trial of Antibody-drug Conjugate (ADC) Called Enfortumab Vedotin
Seattle Genetics and its partner, Astellas, have recently announced that the patients were selected for EV-201, the key phase II clinical trial of an experimental antibody-drug conjugate (ADC) called enfortumab vedotin. TheRead More…
FDA Grants Priority Review for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
On July 18, Immunopharmas, a leading biopharmaceutical company in the field of antibody-drug conjugates, announced that the Biologics License Application (BLA) of its sacituzumab govitecan for the treatment of metastatic triple-negative breastRead More…
Creative Biolabs’s Expert Advanced Professional Opinions in an Exclusive Interview with Biocompare
Recently, Yuning Chen, Ph.D., from Creative Biolabs was exclusively interviewed by Angelo DePalma, a journalist from Biocompare, and shared his forward-looking and professional view on antibody-drug conjugates( ADCs). Antibody-drug conjugates (ADCs) are a new implementationRead More…
Nat Commun: Novel Tumor Targeting Antibody Drugs Conjugation Effectively Treat Colon and Ovarian Cancer
Tagworks Pharmaceuticals in the University of Nijmegen Medical Center has developed a new technology that targets tumor to deliver chemotherapy drugs in extreme cases. By controlling the “click release” of a chemotherapeuticRead More…
Celldex plans Life After Glembatumumab, Cutting 2 More Drugs From Pipeline
Still reeling from the failure of its lead breast cancer candidate glembatumumab vedotin last month, Celldex has culled another two pipeline projects and now says it will focus its R&D efforts mainlyRead More…
Understanding Cancer Heterogeneity May Help Avoid Harmful Effects of Chemotherapy
“Understanding cancer heterogeneity could further reduce chemo use,” says cancer research expert Antonio Giordano, MD, PhD, Director of the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University. “Further studyRead More…
Forward I Phase III Trial of Mirvetuximab Sorvtansine in Platinum-resistant Ovarian Cancer Completes Full Enrollment
The FORWARD I Phase III registration trial (NCT02631876) evaluating the antibody-drug conjugate or ADC mirvetuximab soravtansine as a single-agent therapy for the treatment of platinum-resistant ovarian cancer, has completed full enrollment andRead More…
Antibody–drug Conjugates: Historical Developments
A Simple Concept of Antibody-drug Conjugates (ADCs) Developing new anticancer chemotherapeutic drugs showing superior antitumor efficacy with reduced toxicity is continuing to be a challenging endeavor. Antibody-drug conjugates (ADCs) are an emergingRead More…